Henna Karra
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Henna Karra has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Teijo Kuopio
Department of Education and Research, Hospital Nova of Central Finland, 40620 Jyväskylä, Finland
3 shared publications E Löyttyniemi
Department of Medical Statistics, Medical Faculty, University of Turku, Turku, Finland
1 shared publication- Eliisa Löyttyniemi
Department of Biostatistics, University of Turku, Turku, Finland
1 shared publication H Repo
Department of Pathology, University of Turku and Turku University Central Hospital, Turku, Finland
1 shared publication- Heli Repo
Department of Pathology, The Nova Hospital of Central Finland, Jyväskylä, Finland
1 shared publication I Ahonen
Department of Medical Statistics, Medical Faculty, University of Turku, Turku, Finland
1 shared publication
Latest Publications
- Open Access
- 27 October 2017
- Published by Springer Nature in BMC Cancer
- Vol. 17 (1) , 705
PTTG1-interacting protein (PTTG1IP/PBF) predicts breast cancer survival
PTTG1-interacting protein (PTTG1IP) is an oncogenic protein, which participates in metaphase-anaphase transition of the cell cycle through activation of securin (PTTG1). PTTG1IP promotes the shift of securin from the cell cytoplasm to the nucleus, allowing the interaction between separase and securin. PTTG1IP overexpression has been previously observed in malignant disease, e.g. in breast carcinoma. However, the prognostic value of PTTG1IP in breast carcinoma patients has not previously been revealed. A total of 497 breast carcinoma patients with up to 22-year follow-up were analysed for PTTG1IP and securin immunoexpression. The results were evaluated for correlations with the clinical prognosticators and patient survival. In our material, negative PTTG1IP immunoexpression predicted a 1.5-fold risk of breast cancer death (p = 0.02). However, adding securin immunoexpression to the analysis indicated an even stronger and independent prognostic power in the patient material (HR = 2.5, p < 0.0001). The subcellular location of securin was found with potential prognostic value also among the triple-negative breast carcinomas (n = 96, p = 0.052). PTTG1IP-negativity alone and in combination with high securin immunoexpression indicates a high risk of breast cancer death, resulting in up to 14-year survival difference in our material.
- 27 October 2017
- Published by Springer Nature in BMC Cancer
- Vol. 17 (1) , 705
Open AccessPTTG1-interacting protein (PTTG1IP/PBF) predicts breast cancer survival
PTTG1-interacting protein (PTTG1IP) is an oncogenic protein, which participates in metaphase-anaphase transition of the cell cycle through activation of securin (PTTG1). PTTG1IP promotes the shift of securin from the cell cytoplasm to the nucleus, allowing the interaction between separase and securin. PTTG1IP overexpression has been previously observed in malignant disease, e.g. in breast carcinoma. However, the prognostic value of PTTG1IP in breast carcinoma patients has not previously been revealed. A total of 497 breast carcinoma patients with up to 22-year follow-up were analysed for PTTG1IP and securin immunoexpression. The results were evaluated for correlations with the clinical prognosticators and patient survival. In our material, negative PTTG1IP immunoexpression predicted a 1.5-fold risk of breast cancer death (p = 0.02). However, adding securin immunoexpression to the analysis indicated an even stronger and independent prognostic power in the patient material (HR = 2.5, p < 0.0001). The subcellular location of securin was found with potential prognostic value also among the triple-negative breast carcinomas (n = 96, p = 0.052). PTTG1IP-negativity alone and in combination with high securin immunoexpression indicates a high risk of breast cancer death, resulting in up to 14-year survival difference in our material.
- Open Access
- 22 May 2014
- Published by Springer Nature in British Journal of Cancer
- Vol. 110 (12) , 2905-2913
Cdc20 and securin overexpression predict short-term breast cancer survival
Cdc20 is an essential component of cell division and responsible for anaphase initiation regulated by securin degradation. Cdc20 function is strongly regulated by the spindle assembly checkpoint to ensure the timely separation of sister chromatids and integrity of the genome. We present the first results on Cdc20 in a large clinical breast cancer material. The study was based on 445 breast cancer patients with up to 20 years of follow-up (mean 10.0 years). DNA content was determined by image cytometry on cell imprints, and Cdc20 and securin immunohistochemistry on tissue microarrays of breast cancer tissue. In our results, high Cdc20 and securin expression was associated with aneuploid DNA content. In prognostic analyses, high Cdc20 immunoexpression alone and in combination with high securin immunoexpression indicated aggressive course of disease and up to 6.8-fold (P<0.001) risk of breast cancer death. Particularly, high Cdc20 and securin immunoexpression identified a patient subgroup with extremely short, on average 2.4 years, breast cancer survival and triple-negative breast cancer (TNBC) subtype. We report for the first time the association of high Cdc20 and securin immunoexpression with extremely poor outcome of breast cancer patients. Our experience indicates that Cdc20 and securin are promising candidates for clinical applications in breast cancer prognostication, especially in the challenging prognostic decisions of TNBC.
- 22 May 2014
- Published by Springer Nature in British Journal of Cancer
- Vol. 110 (12) , 2905-2913
Open AccessCdc20 and securin overexpression predict short-term breast cancer survival
Cdc20 is an essential component of cell division and responsible for anaphase initiation regulated by securin degradation. Cdc20 function is strongly regulated by the spindle assembly checkpoint to ensure the timely separation of sister chromatids and integrity of the genome. We present the first results on Cdc20 in a large clinical breast cancer material. The study was based on 445 breast cancer patients with up to 20 years of follow-up (mean 10.0 years). DNA content was determined by image cytometry on cell imprints, and Cdc20 and securin immunohistochemistry on tissue microarrays of breast cancer tissue. In our results, high Cdc20 and securin expression was associated with aneuploid DNA content. In prognostic analyses, high Cdc20 immunoexpression alone and in combination with high securin immunoexpression indicated aggressive course of disease and up to 6.8-fold (P<0.001) risk of breast cancer death. Particularly, high Cdc20 and securin immunoexpression identified a patient subgroup with extremely short, on average 2.4 years, breast cancer survival and triple-negative breast cancer (TNBC) subtype. We report for the first time the association of high Cdc20 and securin immunoexpression with extremely poor outcome of breast cancer patients. Our experience indicates that Cdc20 and securin are promising candidates for clinical applications in breast cancer prognostication, especially in the challenging prognostic decisions of TNBC.
- 19 January 2012
- Published by Wiley in Histopathology
- Vol. 60 (4) , 586-596
Securin predicts aneuploidy and survival in breast cancer
Karra H, Pitkänen R, Nykänen M, Talvinen K, Kuopio T, Söderström M & Kronqvist P (2012) Histopathology 60, 586–596 Securin predicts aneuploidy and survival in breast cancerAims: Securin is known to participate in maintaining chromosomal integrity during the cell cycle through regulation of metaphase–anaphase transition, DNA damage repair, and apoptosis. The aim of this study was to investigate the role of securin in aneuploidy and prognosis in human breast cancer.Methods and results: The study was based on 603 breast cancer patients with up to 20 years of follow‐up. DNA content was determined by image cytometry on cell imprints, and securin immunohistochemistry was performed on tissue microarrays of breast cancer tissue. We show, for the first time in human breast cancer, that high‐level securin expression predicts abnormal DNA content, with up to 9.8‐fold odds for aneuploid DNA content (P = 0.0007). Securin also shows strong independent prognostic value for disease‐specific survival, with a significant difference in survival time between patients with low‐level and high‐level securin expression.Conclusions: The main result of the present study is the association of aneuploidy and securin expression. According to our results, securin immunohistochemistry is also a potential new prognosticator for treatment decisions concerning breast cancer patients.
- 19 January 2012
- Published by Wiley in Histopathology
- Vol. 60 (4) , 586-596
Securin predicts aneuploidy and survival in breast cancer
Karra H, Pitkänen R, Nykänen M, Talvinen K, Kuopio T, Söderström M & Kronqvist P (2012) Histopathology 60, 586–596 Securin predicts aneuploidy and survival in breast cancerAims: Securin is known to participate in maintaining chromosomal integrity during the cell cycle through regulation of metaphase–anaphase transition, DNA damage repair, and apoptosis. The aim of this study was to investigate the role of securin in aneuploidy and prognosis in human breast cancer.Methods and results: The study was based on 603 breast cancer patients with up to 20 years of follow‐up. DNA content was determined by image cytometry on cell imprints, and securin immunohistochemistry was performed on tissue microarrays of breast cancer tissue. We show, for the first time in human breast cancer, that high‐level securin expression predicts abnormal DNA content, with up to 9.8‐fold odds for aneuploid DNA content (P = 0.0007). Securin also shows strong independent prognostic value for disease‐specific survival, with a significant difference in survival time between patients with low‐level and high‐level securin expression.Conclusions: The main result of the present study is the association of aneuploidy and securin expression. According to our results, securin immunohistochemistry is also a potential new prognosticator for treatment decisions concerning breast cancer patients.